Advertisement

Validity of International Classification of Diseases Codes for Sickle Cell Trait and Sickle Cell Disease

  • Kabir O. OlaniranEmail author
  • Harish Seethapathy
  • Sophia H. Zhao
  • Andrew S. Allegretti
  • Sahir Kalim
  • Sagar U. Nigwekar
Concise Research Report
  • 16 Downloads

INTRODUCTION

Sickle cell trait (SCT) is increasingly being studied as a risk factor for diseases disproportionately affecting African Americans.1 Research into sickle cell disease (SCD) is also increasing due to poor outcomes in this understudied condition.2 Most sickle cell research uses hemoglobin electrophoresis or genetic data to identify patients. However, such information is not always collected or available in clinical care records, limiting adequate sample sizes in large databases with useful outcomes. The utility of International Classification of Diseases (ICD) codes to determine sickle cell status has not been examined in detail. We sought to determine sickle cell prevalence and the validity of sickle cell ICD codes in African American adults in a large multi-hospital healthcare system.

METHODS

We reviewed all adult African American patients with a hemoglobin electrophoresis in the patients’ data registry of Partners Healthcare, Boston Massachusetts. Hemoglobin...

KEY WORDS

sickle cell trait sickle cell disease ICD validity 

Notes

Acknowledgments

K.O.O. is supported by the Ben J. Lipps Research Fellowship Award of the American Society of Nephrology. A.S.A is supported by the American Heart Association Career Development Award 18CDA34110131. S.U.N. is supported by the National Center for Research Program Winter 2015 Fellow-to-Faculty Transition Award 15FTF25980003 from the American Heart Association and by the KL2/Catalyst Medical Research Investigator Training award TR001100 (an appointed KL2 award) from Harvard Catalyst, the Harvard Clinical and Translational Science Center (National Center for Research Resources, and the National Center for Advancing Translational Sciences, National Institutes of Health). S.K. is supported by National Institutes of Health award K23 DK 106479.

Compliance with Ethical Standards

This study was approved by the Institutional Review Board at Partners Healthcare, Boston Massachusetts and the need for informed consent was waived.

Conflict of Interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Naik RP, Haywood C. Sickle cell trait diagnosis: clinical and social implications. Hematol Am Soc Hematol Educ Progr 2015;2015(1):160-167. doi: https://doi.org/10.1182/asheducation-2015.1.160 CrossRefGoogle Scholar
  2. 2.
    Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet (London, England). 2010;376(9757):2018-2031. doi: https://doi.org/10.1016/S0140-6736(10)61029-X CrossRefGoogle Scholar
  3. 3.
    Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol 2015;11(3):161-171. doi: https://doi.org/10.1038/nrneph.2015.8 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. Incidence of Sickle Cell Trait — United States, 2010. Morbidity and Mortality Weekly Report. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a3.htm. Published 2014. Accessed June 2, 2017.
  5. 5.
    Centers for Disease Control and Prevention. Data and Statistics | Sickle Cell Disease | NCBDDD | CDC. Sickle Cell Disease Homepage. https://www.cdc.gov/ncbddd/sicklecell/data.html. Published 2016. Accessed June 8, 2017.

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  1. 1.Division of Nephrology, Massachusetts General Hospital Harvard Medical SchoolBostonUSA
  2. 2.Division of Nephrology University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations